Recent Investment Analysts’ Ratings Updates for Icon (ICLR)

A number of firms have modified their ratings and price targets on shares of Icon (NASDAQ: ICLR) recently:

  • 5/10/2019 – Icon was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 5/3/2019 – Icon was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 4/24/2019 – Icon was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $146.00 price target on the stock. According to Zacks, “ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide. “
  • 4/23/2019 – Icon was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 4/17/2019 – Icon had its “hold” rating reaffirmed by analysts at Barclays PLC. They now have a $154.00 price target on the stock.
  • 4/16/2019 – Icon was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 4/13/2019 – Icon was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 4/4/2019 – Icon was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 4/2/2019 – Icon is now covered by analysts at Wolfe Research. They set an “outperform” rating on the stock.
  • 3/18/2019 – Icon had its price target raised by analysts at Barclays PLC from $140.00 to $148.00. They now have an “equal weight” rating on the stock.
  • 3/15/2019 – Icon was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Shares of ICLR traded up $0.44 during trading hours on Tuesday, reaching $136.08. 240,676 shares of the company’s stock traded hands, compared to its average volume of 306,931. The firm has a market capitalization of $7.32 billion, a price-to-earnings ratio of 21.63, a price-to-earnings-growth ratio of 1.90 and a beta of 0.62. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.18 and a current ratio of 2.02. Icon Plc has a twelve month low of $117.50 and a twelve month high of $155.33.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, May 1st. The medical research company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.03. The company had revenue of $674.85 million for the quarter, compared to analyst estimates of $668.93 million. Icon had a return on equity of 25.71% and a net margin of 12.56%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period last year, the company earned $1.44 earnings per share. Analysts forecast that Icon Plc will post 6.87 EPS for the current fiscal year.



Large investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in Icon during the fourth quarter worth about $84,127,000. Blackcrane Capital LLC acquired a new position in Icon during the fourth quarter worth about $19,576,000. Morgan Stanley grew its holdings in Icon by 41.4% during the third quarter. Morgan Stanley now owns 82,894 shares of the medical research company’s stock worth $12,745,000 after acquiring an additional 24,256 shares during the period. Chartwell Investment Partners LLC grew its holdings in Icon by 34.3% during the fourth quarter. Chartwell Investment Partners LLC now owns 62,906 shares of the medical research company’s stock worth $8,128,000 after acquiring an additional 16,065 shares during the period. Finally, Financial Gravity Companies Inc. acquired a new position in Icon during the fourth quarter worth about $292,000. 87.76% of the stock is currently owned by hedge funds and other institutional investors.

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Read More: Book Value Per Share – BVPS

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.